Roche Holding AG (ROGZ.XC)
- Previous Close
269.90 - Open
266.90 - Bid 272.60 x --
- Ask 272.80 x --
- Day's Range
266.90 - 273.90 - 52 Week Range
218.10 - 313.80 - Volume
210,444 - Avg. Volume
251,823 - Market Cap (intraday)
216.154B - Beta (5Y Monthly) 0.22
- PE Ratio (TTM)
26.47 - EPS (TTM)
10.30 - Earnings Date Jul 24, 2025
- Forward Dividend & Yield 9.70 (3.56%)
- Ex-Dividend Date Mar 27, 2025
- 1y Target Est
--
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
www.roche.com103,249
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ROGZ.XC
View MorePerformance Overview: ROGZ.XC
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ROGZ.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ROGZ.XC
View MoreValuation Measures
Market Cap
218.74B
Enterprise Value
237.77B
Trailing P/E
26.44
Forward P/E
13.44
PEG Ratio (5yr expected)
0.68
Price/Sales (ttm)
3.50
Price/Book (mrq)
6.83
Enterprise Value/Revenue
3.81
Enterprise Value/EBITDA
14.31
Financial Highlights
Profitability and Income Statement
Profit Margin
13.27%
Return on Assets (ttm)
12.75%
Return on Equity (ttm)
26.47%
Revenue (ttm)
62.39B
Net Income Avi to Common (ttm)
8.28B
Diluted EPS (ttm)
10.30
Balance Sheet and Cash Flow
Total Cash (mrq)
17.33B
Total Debt/Equity (mrq)
100.60%
Levered Free Cash Flow (ttm)
13.67B